Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis

Furie, Richard; H. Rovin, Brad; Houssiau, Frédéric; Malvar, Ana; K Onno Teng, Y; Contreras, Gabriel; Amoura, Zahir; Yu, Xueqing; Mok, Chi-Chiu; B. Santiago, Mittermayer; Saxena, Amit; Green, Yulia; Ji, Beulah; Kleoudis, C.; W. Burriss, Susan; Barnett, Carly; A. Roth, David

doi:10.1056/nejmoa2001180

Public

Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis

Published in New England Journal of Medicine • Sep 16, 2020

Authors:

Richard Furie

Brad H. Rovin

Frédéric Houssiau

Abstract

BACKGROUND: In adults with active lupus nephritis, the efficacy and safety of intravenous belimumab as compared with placebo, when added to standard therapy (mycophenolate mofetil or cyclophosphamide-azathioprine), are unknown. METHODS: , and no use of rescue therapy). The time to a renal-related ev...

Subject

Belimumab

Lupus nephritis

Azathioprine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!